Fact CheckerSign in

NCT05807646Not yet recruiting

Reduced Dissemination of Tumor Cells With Primary Ligation of the Inferior Mesenteric Vein in Rectal Cancer Patients.

Effect of Ligation Sequence of the Inferior Mesenteric Artery and Vein on Circulating Tumor Cells and Survival in Laparoscopic Rectal Cancer Surgery: a Prospective, Multicenter, Randomized Controlled Study (ARVECTS)

Source: ClinicalTrials.gov · Last updated 15 Feb 2024 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Effect of ligation sequence of the inferior mesenteric artery and vein on circulating tumor cells and survival in laparoscopic rectal cancer surgery: a prospective, multicenter, randomized controlled study (ARVECTS)

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
268 (estimated)
First submitted
29 Mar 2023
Start date
Jan 2025
Primary completion date
Dec 2025
Lead sponsor
Sichuan Cancer Hospital and Research Institute
NCT number
NCT05807646

What you commit to

  • Study type: Interventional
  • Planned participants: 268
  • From Jan 2025 to the primary completion date, Dec 2025
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Patients who have received preoperative treatment (such as preoperative radiotherapy and chemotherapy);
  • Receiving transanal total mesorectal excision (taTME), specimen extraction through natural lumen (NOSES) ;
  • The results of preoperative physical examination and imaging examination showed that: (1) the tumor involved the surrounding organs and required combined organ resection; (2) distant metastasis; (3) could not be resected at R0;
  • It is not suitable for patients undergoing laparoscopic surgery (such as extensive adhesion caused by previous abdominal surgery or inability to tolerate artificial pneumoperitoneum);
  • Systemic administration of corticosteroids within 1 month before enrollment;
  • Taking folic acid related drugs within half a year before operation.
  • Emergency surgery.

Other illness

  • Recurrent rectal cancer;
  • Simultaneous or metachronous colorectal cancer;
  • Malignant tumors of other organs in the past 5 years or at the same time;
  • Patients with severe mental disorder;
  • History of unstable angina pectoris or myocardial infarction in the past 6 months;
  • Have a history of cerebrovascular accident in the past 6 months;
  • Severe cardiac insufficiency (FEV1\<50% of predicted values);

Other

  • Pregnant or lactating women;

Who the study is looking for

  • Age: 18-75 years;
  • Histopathologically confirmed as rectal adenocarcinoma(tumor located within 15 cm from the anal verge at colonoscopy);
  • Patients with a stage I-III rectal cancer eligible for surgery and R0 resection is expected, patients with pelvic lateral lymph nodes metastasis are ineligible;
  • ECOG score: 0-1;
  • ASA score: I/II/III;
  • Laparoscopic surgery;
  • Informed consent.

Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.